Evidence map›Paper›PMID 42179652›Full record

ReviewiLIVER2026

Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications.

Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wen KangDepartment of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi, China.
Yu-Shen LiuDepartment of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi, China.
Tian-Ping WangDepartment of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi, China.
Shu-Ming ZhangSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China.
Yu LiDepartment of Infectious Diseases, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi, China.
Ye ZhangDepartment of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC). The functional cure for chronic hepatitis B (CHB), defined as sustained hepatitis B surface antigen (HBsAg) seroclearance for at least 24 weeks, undetectable hepatitis B e antigen and HBV DNA, and normalized liver functions, has emerged as a pivotal therapeutic goal due to its association with a significant reduction in long-term complications, particularly HCC. This review comprehensively summarizes the epidemiological burden of HBV-related HCC, elucidates the mechanisms underlying HBV-induced hepatocarcinogenesis, and identifies the key risk factors for HCC development in CHB patients,

Indexed as

Antiviral therapyChronic hepatitis BFunctional cureHepatocellular carcinomaNucleos(t)ide analogsPegylated interferon-α

Identifiers

PMID42179652
PMCPMC13196358

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.